![\"A](\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/01\/health-high-five-16_9-1200x675.jpg\")
<\/p>\n<\/p>\n
Image source: Getty Images<\/p>\n
These 3 ASX healthcare shares have all had their fair share of issues over the past few months.<\/p>\n
Investors walked out, and as a result the share prices of CSL Ltd (ASX: CSL<\/a>), Sigma Healthcare Ltd (ASX:SIG<\/a>) and Sonic Healthcare Ltd have been under pressure.<\/p>\n But it’s not all pain and pills. Brokers see potential 15-35% upside for these quality ASX healthcare shares<\/a>. <\/p>\n Let’s go and check them out.<\/p>\n CSL, the $85 billion healthcare heavyweight, has had a proper clanger of a year. The share price slid as investors panicked over high plasma collection costs, sluggish margin recovery and patchy vaccine demand.<\/p>\n For a stock once treated like a superannuation heirloom \u2014 buy it, forget it, brag about it \u2014 the stumble has been confronting.<\/p>\n But here’s the plot twist. This ASX healthcare share hasn’t forgotten how to grow. Plasma volumes are ticking up, cost pressures are easing and management insists margins can recover with a bit of patience and fewer market tantrums.<\/p>\n This year doesn’t need to be heroic. It just needs to be less disappointing for sentiment to flip. Yes, execution matters and margins must recover.<\/p>\n Still, analysts remain bullish, tipping an average 12-month price target of $232.15. That points to a 34%, suggesting the market may have overdone the exodus.<\/p>\n Sigma Healthcare Ltd (ASX: SIG<\/a>)<\/p>\n Sigma Healthcare hasn’t been feeling the love lately \u2014 and it’s not hard to see why.<\/p>\n First up: merger mayhem. The Chemist Warehouse tie-up sent integration and transaction costs through the roof, smashing near-term profits and rattling investors.<\/p>\n Then there’s the hangover from past mistakes. A bungled ERP rollout a few years back snarled supply chains, drove pharmacies into competitors’ arms, and bruised the credibility of the ASX healthcare share.<\/p>\n But it’s not all bad news. The Chemist Warehouse merger supercharges Sigma’s scale, plugging wholesale, distribution and retail into one powerful machine. If the synergies land, earnings could follow.<\/p>\n Tailwinds help too. Australia’s ageing population and steady demand for health products keep the long-term story intact.<\/p>\n Analysts see strong scale, improved EBITDA<\/a> and a growing network which give the ASX healthcare share defensive cash flows and growth runway. A rare thing in healthcare retail.<\/p>\n Brokers predict 12-month average price targets of around $3.30, which implies a potential gain of almost 15% above current levels of $2.90.<\/p>\n